LAVA Therapeutics NV Cash Flow Conversion Efficiency
LAVA Therapeutics NV cash flow conversion efficiency. Based on the latest financial reports, LAVA Therapeutics NV (LVTX) has a cash flow conversion efficiency ratio of -0.384x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.87 Million) by net assets ($12.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of LAVA Therapeutics NV (2019–2024)
Cash flow conversion efficiency of LAVA Therapeutics NV from 2019 to 2024. This chart illustrates how LAVA Therapeutics NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. View LVTX share price today for real-time trading data and today's change.
LAVA Therapeutics NV Cash Flow Conversion Ratio Explained
LAVA Therapeutics NV cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
LAVA Therapeutics NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LAVA Therapeutics NV ranked by their cash flow conversion efficiency. Also see LVTX market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hyundai Industrial Co. Ltd
KQ:170030
|
-0.005x |
|
Mercal Inmuebles Socimi SA
MC:YMEI
|
-0.002x |
|
LGL Group Inc
NYSE MKT:LGL
|
0.011x |
|
Taiwan Taffeta Fabric Co Ltd
TW:1454
|
-0.004x |
|
I-Hwa Industrial Co Ltd
TW:1456
|
-0.042x |
|
Deswell Industries Inc
NASDAQ:DSWL
|
0.027x |
|
ImageneBio, Inc.
NASDAQ:IMA
|
-0.064x |
|
PS Tec. Co. Ltd
KQ:002230
|
0.036x |
Annual Cash Flow Conversion Efficiency for LAVA Therapeutics NV (2019–2024)
The table below shows the annual cash flow conversion efficiency of LAVA Therapeutics NV from 2019 to 2024. Review LAVA Therapeutics NV (LVTX) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $27.75 Million | $-19.54 Million | -0.704x | +10.51% |
| 2023-12-31 | $51.18 Million | $-40.28 Million | -0.787x | -1775.08% |
| 2022-12-31 | $86.04 Million | $4.04 Million | 0.047x | +119.42% |
| 2021-12-31 | $118.37 Million | $-28.65 Million | -0.242x | +80.18% |
| 2020-12-31 | $7.62 Million | $-9.31 Million | -1.221x | +17.16% |
| 2019-12-31 | $5.84 Million | $-8.62 Million | -1.474x | -- |
About LAVA Therapeutics NV
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage can… Read more